Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue European Journal of Neurology Année : 2020

Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders

Résumé

Background: Outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown. Methods: We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID-19 between 1 March 2020 and 30 June 2020. Main outcome was COVID-19 severity score assessed on a seven-point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death). Results: Fifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24-year-old patient with positive aquaporine-4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti-CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0-4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0-6.5]). Conclusions: COVID-19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID-19; however, we recommend personal protective measures to reduce risk of SARS-CoV-2 infection in this immunocompromised population.
Fichier principal
Vignette du fichier
NMO_COVID_ejn_revised_clean.pdf (176.64 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03274737 , version 1 (14-12-2021)

Identifiants

Citer

Céline Louapre, Elisabeth Maillart, Caroline Papeix, Sinead Zeidan, Damien Biotti, et al.. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. European Journal of Neurology, 2020, 28 (10), pp.3461-3466. ⟨10.1111/ene.14612⟩. ⟨hal-03274737⟩
114 Consultations
96 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More